Citing COVID-19 disruptions, Novocure (NASDAQ:NVCR) announces that
the expansion of clinical trial sites has been “materially delayed,”
adding that the timing of enrollment and completion of studies will most
likely be extended by multiple quarters.
Management will update investors on its pipeline during its Q1 earnings call.
https://seekingalpha.com/news/3558131-covidminus-19-throttles-trial-site-expansion-novocure
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.